Li Yang, Lin Yan, Shi Zhixiang, Hu Yuxuan, Shao Taihang, Li Mengyuan, Zhu Jiawen, Sun Lizhou, Chang Feng
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Ann Transl Med. 2021 Sep;9(18):1407. doi: 10.21037/atm-21-782.
Sanqi injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze the published reports of efficacy and safety of Sanqi injection and safflower yellow injection for the treatment of acute cerebral infarction. The cost-effectiveness of these drug formulations was also evaluated.
China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, VIP, PubMed, Embase, and the Chinese Biomedical Literature (CBM) were searched with the restrictions keywords in Chinese and English between 2006 and 2019 to obtain RCTs. A meta-analysis and a meta-regression analysis were undertaken in Reviewer Manager 5.3 software to compare the efficacy and safety of Sanqi and safflower yellow injection. This study used a decision tree model to analyze the cost-effectiveness of the two treatments. The TreeAge Pro software was used to comprehensively evaluate the economics of these medications.
Twelve papers were all randomized controlled trials (RCTs) in which Sanqi injection was applied in the control group, while safflower yellow injection was applied in the experimental group and the quality of them were good. The results of the 12 papers were compared, and the total effective rate of the treatment group (91.18%) was significant and showed no significant difference with the control group (74.83%) (RR =1.24, 95% CI: 1.19, 1.30, P<0.00001). From the perspective of pharmacoeconomics, compared with Sanqi group, the ICER of safflower yellow injection is 3,885.75 RMB. The sensitivity analysis results were consistent with the basic analysis results, indicating that the basic analysis results were relatively stable.
Comparing with Sanqi injection, safflower yellow injection and related combination therapy can improve the total effective rate and are safer with fewer adverse reactions. It is also more cost-effective than the use of Sanqi injection.
三七注射液和红花黄色素注射液是用于治疗心血管疾病的中药注射剂,在公立医院被广泛用于治疗急性脑梗死患者。本研究旨在比较和分析三七注射液和红花黄色素注射液治疗急性脑梗死的疗效和安全性的已发表报告。同时还评估了这些药物制剂的成本效益。
检索中国知网(CNKI)、万方、维普、中国生物医学文献数据库(CBM)、PubMed、Embase等数据库,使用中英文限定关键词检索2006年至2019年期间的随机对照试验(RCT)。在Reviewer Manager 5.3软件中进行荟萃分析和荟萃回归分析,以比较三七注射液和红花黄色素注射液的疗效和安全性。本研究使用决策树模型分析两种治疗方法的成本效益。使用TreeAge Pro软件综合评估这些药物的经济学。
12篇论文均为随机对照试验,其中三七注射液应用于对照组,红花黄色素注射液应用于试验组,且质量良好。比较12篇论文的结果,治疗组的总有效率(91.18%)显著高于对照组(74.83%)(RR =1.24,95%CI:1.19,1.30,P<0.00001)。从药物经济学角度来看,与三七组相比,红花黄色素注射液的增量成本效果比为3885.75元。敏感性分析结果与基本分析结果一致,表明基本分析结果相对稳定。
与三七注射液相比,红花黄色素注射液及相关联合治疗可提高总有效率,安全性更高,不良反应更少。而且比使用三七注射液更具成本效益。